Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report)'s stock price shot up 1.3% during trading on Friday . The stock traded as high as $1.52 and last traded at $1.52. 4,448 shares traded hands during trading, a decline of 63% from the average session volume of 12,182 shares. The stock had previously closed at $1.50.
Wall Street Analyst Weigh In
Separately, HC Wainwright lowered Adlai Nortye from a "buy" rating to a "neutral" rating in a report on Monday, June 2nd.
Get Our Latest Stock Report on ANL
Adlai Nortye Trading Up 1.3%
The company has a fifty day simple moving average of $1.66 and a 200-day simple moving average of $1.95. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.41 and a quick ratio of 1.41.
About Adlai Nortye
(
Get Free Report)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Read More
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
